Exogenous human urinary kallidinogenase increases cerebral blood flow in patients with acute ischemic stroke

To study the effects of human urinary kallidinogenase (HUK) treatment on acute cerebral ischemia (ACI) using magnetic resonance perfusion weighted imaging (MRP) methods.

In a non-randomized controlled clinical trial, 30 patients diagnosed with ACI were enrolled and divided manually into 2 groups. The experimental group, consisting of 18 participants, was treated with HUK (0.15 Perinatal Assessment Unit/day) for 7 consecutive days. The control group was treated with routine medication. The participants underwent MRP examination on the first and fourteenth day after onset. The National Institutes of Health Stroke Scale (NIHSS) score, cerebral blood flow (CBF), cerebral blood volume (CBV), mean transit time (MTT), and time to peak (TTP) were compared between the groups.

After undergoing therapy, the experimental HUK-treated group had lower NIHSS scores than the control group (p<0.05). The CBF improved more in the HUK-treated group than in the control group (p<0.05). Additionally, MTT and TTP were shorter in the HUK-treated group than in the control group (p<0.05).

Human urinary kallidinogenase improves CBF and ameliorates neurological deficits. Human urinary kallidinogenase is a safe and effective treatment approach for treating patients with ACI.